Beximco Pharma declares 47.5% cash dividend, makes Tk699.88cr profit in FY25
During the fiscal year, its consolidated net profit stood at Tk699.88 crore, which was Tk586.67 crore.
Beximco Pharmaceuticals recommended a 47.5% cash dividend to its shareholders for the fiscal year 2024-25 ended 30 June.
The company declared the dividend at a board meeting held today (23 June), according to the company source.
During the fiscal year, its consolidated net profit stood at Tk699.88 crore, which was Tk586.67 crore.
Keep updated, follow The Business Standard's Google news channel
To approve the audited financial statement and the dividend the company will set the annual general meeting time and venue following the High Court order. It also set the record date for 2 August.
Besides, the company reported that its consolidated net profit stood at Tk704 crore in the first nine months of FY26.
Earlier, the regulator had permitted the Beximco Pharma to hold a special board meeting to approve and publish its five overdue quarterly financial statements, mitigating the looming risk of a delisting from the London Stock Exchange (LSE).
The trading of Beximco Pharma remained temporarily suspended on London's Alternative Investment Market (AIM) from 2 January 2026, as it failed to publish its annual financial results within the stipulated time frame.
Amid rising concerns raised by foreign institutional investors to the Bangladesh Securities and Exchange Commission (BSEC), the regulator has permitted Beximco Pharmaceuticals to hold a board of directors meeting.
During the interim government, the BSEC appointed nine independent directors to the board of Beximco Pharma, as well as to two other listed group entities: Beximco Ltd and Shinepukur Ceramics.
Beximco Pharma legally challenged the regulator's decision by filing a writ petition, which remains pending in court. Citing the matter as sub-judice, the company has not allowed the BSEC-appointed independent directors to take their seats on the board.
